The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 20, 2011
Filed:
Apr. 24, 2009
Carsten Schubert, Phoenixville, PA (US);
Bruce L. Grasberger, Trappe, PA (US);
Celine Schalk-hihi, Phoenixville, PA (US);
Diane M. Maguire, Downingtown, PA (US);
Frank A. Lewandowski, Washington Crossing, PA (US);
Cynthia M. Milligan, Rutledge, PA (US);
Richard S. Alexander, Newark, DE (US);
Carsten Schubert, Phoenixville, PA (US);
Bruce L. Grasberger, Trappe, PA (US);
Celine Schalk-Hihi, Phoenixville, PA (US);
Diane M. Maguire, Downingtown, PA (US);
Frank A. Lewandowski, Washington Crossing, PA (US);
Cynthia M. Milligan, Rutledge, PA (US);
Richard S. Alexander, Newark, DE (US);
Janssen Pharmaceutica N.V., Beerse, BE;
Abstract
A number of soluble engineered forms of MGLL that are suitable for high-throughput screening and protein crystallization, as well as a crystallized form of monoacylglycerol lipase protein (MGLL) and descriptions of the X-ray diffraction patterns are disclosed. The engineered constructs of MGLL permit the expression and purification of protein suitable for crystallography or high-throughput screening and identification of ligands, which can function as active agents to MGLL. The X-ray diffraction patterns allow the three dimensional structure of MGLL to be determined at atomic resolution so that ligand binding sites on MGLL can be identified and the interactions of ligands with MGLL amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of MGLL.